Schedule 13G ownership disclosure
Corvus Pharmaceuticals Inc
Common Stock, par value $0.0001 per share · CUSIP: 221015100
Event date: 2025-03-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- SAMLYN CAPITAL, LLC
Shares: 4,065,935.00 · Class: 6.0%
- SAMLYN, LP
Shares: 4,065,935.00 · Class: 6.0%
- ROBERT POHLY
Shares: 4,065,935.00 · Class: 6.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000919574-25-003240
- Form type
- SCHEDULE 13G/A
- Filer
- Corvus Pharmaceuticals, Inc.
- CIK
- CIK 1626971
- Filed
- May 15, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership